A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2016
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 12 Mar 2016 Results (n=28) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 26 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Oct 2014 Planned End Date changed from 1 Oct 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.